Associated Papers
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.
Burge RA et al.
Cancer Research, 2026
DA-Raf synergistically binds to the plasma membrane and Ras to suppress ERK signaling.
Takano K et al.
Life Science Alliance, 2025
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.
Kamgar M et al.
Cancer Research, 2025
Pancreatic Cells Are Resistant to KRASQ61L Expression due to Hyperactive ERK/MAPK Signaling and Apoptosis Induction.
Burge RA et al.
Cancer Research Communications, 2025
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
Different Ras isoforms regulate synaptic plasticity in opposite directions.
López-Merino E et al.
The Embo Journal, 2025
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex.
Damianou A et al.
Life Science Alliance, 2024
Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex.
Vasta JD et al.
Cell Chemical Biology, 2023
Beyond Structural Bioinformatics for Genomics with Dynamics Characterization of an Expanded KRAS Mutational Landscape.
Ratnasinghe BD et al.
Biorxiv : the Preprint Server for Biology, 2023
Beyond structural bioinformatics for genomics with dynamics characterization of an expanded KRAS mutational landscape.
Ratnasinghe BD et al.
Computational and Structural Biotechnology Journal, 2023
Multiomic analysis of papillary thyroid cancers identifies BAIAP2L1-BRAF fusion and requirement of TRIM25, PDE5A and PKCδ for tumorigenesis.
Renaud E et al.
Molecular Cancer, 2022
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
Yang Y et al.
Nature Communications, 2022
A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions.
Miller SP et al.
Molecular & Cellular Proteomics : Mcp, 2022
Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H et al.
Nature Communications, 2021
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
Mutation patterns in recurrent and/or metastatic oropharyngeal squamous cell carcinomas in relation to human papillomavirus status.
Reder H et al.
Cancer Medicine, 2021
Galectin-8 binds to the Farnesylated C-terminus of K-Ras4B and Modifies Ras/ERK Signaling and Migration in Pancreatic and Lung Carcinoma Cells.
Meinohl C et al.
Cancers, 2019
Genetic alterations in human papillomavirus-associated oropharyngeal squamous cell carcinoma of patients with treatment failure.
Reder H et al.
Oral Oncology, 2019
K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function.
Cao S et al.
The Journal of Biological Chemistry, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.
Bery N et al.
Elife, 2018
DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Kanno E et al.
Experimental Cell Research, 2018
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.
Jin T et al.
Nature Communications, 2017
Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma.
Hirotsu Y et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology, 2016
OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination.
Baietti MF et al.
Embo Molecular Medicine, 2016
Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
Kim EY et al.
Bmc Cancer, 2016
Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.
Alakus H et al.
Genome Medicine, 2014
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization.
Lavoie H et al.
Nature Chemical Biology, 2013
Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors.
Sasaki AT et al.
Science Signaling, 2011
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer.
Calvisi DF et al.
Journal of Hepatology, 2011
Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands.
Tetsu O et al.
Neoplasia (new York, N.y.), 2010
RAF protein-serine/threonine kinases: structure and regulation.
Roskoski R
Biochemical and Biophysical Research Communications, 2010
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G et al.
Nature, 2010
Nore1B regulates TCR signaling via Ras and Carma1.
Ishiguro K et al.
Cellular Signalling, 2006
Expression of Rem2, an RGK family small GTPase, reduces N-type calcium current without affecting channel surface density.
Chen H et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 2005
The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation.
Clark GJ et al.
The Journal of Biological Chemistry, 1997
Analysis of K-Ras Interactions by Biotin Ligase Tagging.
Ritchie C et al.
Cancer Genomics & Proteomics, 0
NGS-based profiling of key cancer genes in Indian triple-negative breast cancer patients reinforces molecular heterogeneity of the disease.
Sahasrabuddhe NA et al.
Indian Journal of Cancer, 0